SNOA - Sonoma Pharmaceuticals Inc Stock Price, Fair Value and News

$2.63+0.08 (+3.14%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SNOA Price Action

Last 7 days

-1.5%

Last 30 days

-7.4%

Last 90 days

-24.0%

Trailing 12 Months

-12.3%

SNOA RSI Chart

SNOA Valuation

Market Cap

3.5M

Price/Earnings (Trailing)

-0.96

Price/Sales (Trailing)

0.26

EV/EBITDA

0.16

Price/Free Cashflow

-2.29

SNOA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SNOA Fundamentals

SNOA Revenue

Revenue (TTM)

13.5M

Rev. Growth (Yr)

31.05%

Rev. Growth (Qtr)

5.54%

SNOA Earnings

Earnings (TTM)

-3.7M

Earnings Growth (Yr)

58.89%

Earnings Growth (Qtr)

46.63%

SNOA Profitability

Operating Margin

25.52%

EBT Margin

-27.62%

Return on Equity

-68.87%

Return on Assets

-26.93%

Free Cashflow Yield

-43.7%

SNOA Investor Care

Buy Backs (1Y)

90.21%

Diluted EPS (TTM)

2.06

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	12.7M	12.7M	13.5M	0
2023	13.3M	12.7M	12.1M	12.3M
2022	12.6M	12.9M	12.5M	12.6M
2021	18.6M	16.5M	14.5M	12.5M
2020	17.9M	19.2M	20.2M	20.8M
2019	19.0M	19.1M	18.9M	18.0M
2018	16.7M	17.2M	17.8M	18.2M
2017	12.8M	14.0M	15.5M	17.0M
2016	12.8M	11.8M	10.5M	11.4M
2015	13.9M	14.1M	14.9M	14.2M
2014	13.7M	13.7M	12.9M	12.8M
2013	15.5M	14.8M	14.3M	14.1M
2012	12.7M	13.9M	14.7M	15.5M
2011	9.8M	10.4M	11.6M	12.1M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

CEO	Ms. Amy M. Trombly
WEBSITE	sonomapharma.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	9

Sonoma Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Sonoma Pharmaceuticals Inc? What does SNOA stand for in stocks?

SNOA is the stock ticker symbol of Sonoma Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sonoma Pharmaceuticals Inc (SNOA)?

As of Fri Dec 20 2024, market cap of Sonoma Pharmaceuticals Inc is 3.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNOA stock?

You can check SNOA's fair value in chart for subscribers.

Is Sonoma Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNOA is over valued or under valued. Whether Sonoma Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Sonoma Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNOA.

What is Sonoma Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, SNOA's PE ratio (Price to Earnings) is -0.96 and Price to Sales (PS) ratio is 0.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNOA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sonoma Pharmaceuticals Inc's stock?

In the past 10 years, Sonoma Pharmaceuticals Inc has provided -0.464 (multiply by 100 for percentage) rate of return.